Man Group
GLUE icon

Man Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Man Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,262
Closed -$416K – 2442
2026
Q1 		$416K Buy
25,262
+8,950
+55% +$171K ﹤0.01% 2130
2025
Q4 		$256K Sell
16,312
-24,263
-60% -$327K ﹤0.01% 2070
2025
Q3 		$301K Buy
40,575
+4,184
+11% +$22.2K ﹤0.01% 2002
2025
Q2 		$164K Buy
+36,391
New +$162K ﹤0.01% 2097

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Man Group's GLUE Position: Q2 2026 in Review

Man Group sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 25,262 shares — an estimated $416K sold.

Man Group first reported a position in GLUE in Q2 2025 and held it in 4 quarters. The position peaked at $416K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Man Group reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 25,262 Monte Rosa Therapeutics shares in Q2 2026, an estimated $416K.
  • Man Group first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 4 quarters.
  • Man Group's Monte Rosa Therapeutics position peaked at $416K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.